Exelixis
Exelixis, Inc.
210 E Grand Ave,
South San Francisco, CA 94080
Phone: (650) 837-7000Website: https://www.exelixis.com/Careers: www.exelixis.com/careers
Latest news
- Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
17 September 2021 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
14 January 2019 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
19 December 2017 - Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma
26 April 2016
Drugs Associated with Exelixis, Inc.
Exelixis, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Cabometyx
Generic name: cabozantinib Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors |
9 reviews | 8.3 / 10 |
|
Cometriq
Generic name: cabozantinib Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors |
2 reviews | 1.0 / 10 |
|
Cotellic
Generic name: cobimetinib Drug class: multikinase inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
